查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球癌症診斷市場人工智慧
市場調查報告書
商品編碼
1351021

2023-2030 年全球癌症診斷市場人工智慧

Global Artificial Intelligence in Cancer Diagnostics Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

預計在預測期內（2023-2030年），全球癌症診斷市場人工智慧將以32.5%的年複合成長率成長。癌症診斷中的人工智慧（AI）是一種用於早期癌症診斷的自動化軟體，透過在早期癌症檢測的幫助下，可以為患者提供適當的治療，從而降低死亡率。一些政府增加了醫療保健資訊科技 (IT) 支出，從而改善了全球的醫療保健基礎設施。例如，美國聯邦政府的醫療保健 IT 支出從 2020 年的 1,195 億美元增加到 2021 年的 1,765 億美元。政府為增加癌症診斷中人工智慧輔助技術的採用而採取的更多舉措預計將推動市場成長。

細分市場前景

全球癌症診斷市場中的人工智慧按應用、類型和最終用戶進行細分。根據應用，市場分為篩檢和診斷、腫瘤識別和監測。根據類型，市場細分為乳腺癌、前列腺癌、肺癌、大腸癌以及子宮頸癌、血癌和骨癌等其他癌症。此外，根據最終用戶，市場細分為醫院、診斷中心、研究機構、醫療機構和學術機構。在最終用戶中，由於政府在醫療保健領域的舉措和資金不斷增加，因此診斷中心細分市場預計將佔據相當大的市場佔有率。

預計乳癌細分市場將在全球癌症診斷市場人工智慧中佔據相當大的佔有率

其中，乳癌細分市場預計將佔據相當大的市場佔有率。這種成長歸因於全球乳癌病例的不斷增加。據世界衛生組織 (WHO) 稱，預計 2021 年將有超過 230 萬新發乳癌病例和 685,000 例乳癌死亡病例。此外，大約一半的乳癌發生在沒有特定危險因子的女性身上。因此，利用人工智慧和機器學習等先進技術在早期階段檢測乳癌，進一步促進產業成長。透過在早期發現癌症，可以為患者提供適當的治療，從而降低死亡率。

區域展望

全球癌症診斷市場人工智慧根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於全球癌症病例數量不斷增加，預計北美將在全球市場中佔據顯著佔有率。根據加拿大癌症統計數據，加拿大 43% 的女性和 45% 的男性一生中會罹患癌症。儘管如此，為了解決這個問題，該國正在整個醫療保健產業積極採用人工智慧。

亞太地區癌症診斷市場的全球人工智慧預計將以顯著的年複合成長率成長

預計亞太地區在預測期內將以可觀的年複合成長率成長。區域成長歸因於人工智慧和機器學習在健康領域的日益普及，該地區的幾項政府措施導致政府和私人組織的投資增加。該地區癌症病例的增加也是醫療保健領域採用人工智慧進行早期診斷的促進因素。根據印度醫學研究委員會國家癌症登記計劃 (ICMR-NCRP)，政府向議會通報，該國癌症病例數量預計將從 2022 年的 1,770 萬美元增加到 2025 年的 1,900 萬美元。例如，NITI印度政府的公共政策智庫Aayog 旨在與生物技術部合作建立一個成像生物庫，其中將創建一個包含20,000 多名患者資料的癌症相關病理和放射學圖像的資料庫。

因此，該國正在大力轉向在癌症診斷市場解決方案中採用人工智慧。例如，根據 NCBI 2022 年 4 月的一篇文章，人工智慧輔助大腸鏡檢查將腺瘤檢出率提高到 29%，而傳統大腸鏡檢查的檢出率約為 20%。這點很重要，因為腺瘤檢出率每增加 1%，大腸癌盛行率就會降低 3%。人工智慧允許整合基因組學、電子病歷、放射影像、病理學和社交網路等各種流來預測臨床決策，這有望改善患者的治療結果。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • IBM Corp.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Microsoft Corp.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Pfizer Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 全球人工智慧在癌症診斷市場的應用
    • 篩檢與診斷
    • 腫瘤識別
    • 監視
  • 按類型分類的全球癌症診斷市場人工智慧
    • 乳癌
    • 攝護腺癌
    • 肺癌
    • 大腸直腸癌
    • 其他（子宮頸癌、血癌、骨癌等）
  • 全球人工智慧在癌症診斷市場的最終用戶
    • 醫院
    • 診斷中心
    • 研究機構
    • 醫學研究所和學者

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Therapixel
  • Sophia Genetics SA
  • Freenome Holdings, Inc.
  • Tempus Labs, Inc.
  • Janssen Pharmaceuticals
  • Path AI Inc.
  • DeepMind Technologies Ltd.
  • Cerner Corp.
  • RaySearch Laboratories
  • Flatiron health
  • Whiterabbit.ai
  • Oncology Analytics Inc.
  • Oncora Medical
  • Ibex Medical Analytics Ltd.
  • 4basecare Onco Solutions Pvt. Ltd .
Product Code: OMR2027621

Title: Global Artificial Intelligence in Cancer Diagnostics Market Size, Share & Trends Analysis Report by Application (Screening & Diagnosis, Tumor Identification and Surveillance), by type (Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Others (Cervical Cancer, blood cancer, bone cancer and other)), and by End User (Hospitals, Diagnostic centers, Research Organization, Medical Institute and academics),Forecast Period (2023-2030).

The global artificial intelligence in cancer diagnostics market is anticipated to grow at a CAGR of 32.5% during the forecast period (2023-2030). Artificial Intelligence (AI) in cancer diagnostics is an automated software used for early cancer diagnostics with the help of cancer detection at early stages, proper treatment can be provided to the patients, resulting in low death rates. Several governments have increased their healthcare Information Technology (IT) expenditure, which in turn to improve healthcare infrastructure around the globe. For instance, the healthcare IT spending of the US federal government increased from $119.5 billion in 2020 to $176.5 billion in 2021. Increasing initiatives undertaken by the government to increase the adoption of AI-assisted technologies for cancer diagnosis is expected to boost the market growth.

Segmental Outlook

The global artificial intelligence in cancer diagnostics market is segmented on the application, type, and End user. Based on the application, the market is sub-segmented into screening & diagnosis, tumor identification and surveillance. Based on the type, the market is sub-segmented into breast cancer, prostate cancer, lung cancer, colorectal cancer, and others including cervical cancer, blood cancer, and bone cancer. Further, on the basis of end user, the market is sub-segmented into hospitals, diagnostic centers, research organization, medical institute and academics. Among the end user, the diagnostic centers sub-segment is anticipated to hold a considerable share of the market owing to the increasing government initiatives and funding in healthcare sector.

The Breast Cancer Sub-Segment is Anticipated to Hold a Considerable Share of the Global Artificial Intelligence in Cancer Diagnostics Market

Among the type, the breast cancer sub-segment is expected to hold a considerable share of the market. This growth is attributed to the growing cases of breast cancer globally. According to the World Health Organization (WHO), over 2.3 million new cases and 685,000 fatalities due to breast cancer were estimated in 2021. Additionally, around half of all breast cancers occur in women along with no specific risk factors. Thus, utilizing advanced technologies such as AI & ML in detecting breast cancer supports at early stages further contributing to the industry growth. With the detection of cancer at early stages, proper treatment can be provided to the patients, resulting in low death rates.

Regional Outlook

The global artificial intelligence in cancer diagnostics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the rising number of cancer cases around the globe. According to Canadian Cancer Statistics, 43% of women and 45% of men in Canada would have cancer in their lifetime. Nevertheless, to combat this problem, the country is actively adopting AI across the healthcare industry.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Artificial Intelligence in Cancer Diagnostics Market

The Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to an increasing adoption of AI and ML in health and several government initiatives in the region lead to an increase in investment by government as well as private organizations. Also increasing cases of cancer in the region is a driving factor for AI adoption in healthcare for early diagnostics. According to Indian Council of Medical Research-National Cancer Registry Programme (ICMR-NCRP), the government informed Parliament the number of cancer cases in the country is projected to go up from $17.7 million in 2022 to $19.0 million in 2025. For instance, NITI Aayog, the public policy think tank of the Indian Government, aims to build an Imaging Biobank in association with the Department of Biotechnology, wherein it will create a database of cancer-related pathology and radiology images of more than 20,000 profiles of patients.

Hence, there is considerable shift of the country towards the adoption of the Artificial Intelligence in Cancer Diagnostics market solutions. For instance, according to an article by the NCBI in April 2022, AI-assisted colonoscopy increased the adenoma detection rate to 29% as compared to conventional colonoscopy, which was about 20%. This is important as 1% increase in adenoma detection rate is associated with 3% decrease in colorectal cancer prevalence. AI allows the integration of a wide variety of streams such as genomics, EHR, radiographic images, pathology, and social networks to predict clinical decisions, which is expected to improve patient outcome.

Market Players Outlook

The major companies serving the artificial intelligence in cancer diagnostics market include: IBM Corp, Intel Corp, Pfizer Inc., Microsoft Corp, Janssen Pharmaceuticals, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, PathAI completed the acquisition of Poplar Healthcare PLLC, an independent anatomic pathology laboratory services provider. Through this acquisition, the company would be able to integrate testing services into its existing artificial intelligence-powered pathology platform. Poplar offers specialized testing services in a range of areas, from oncology to women's health to dermatology.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global artificial intelligence in cancer diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. IBM Corp.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Microsoft Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Artificial Intelligence in Cancer Diagnostics Market by Application
    • 4.1.1. Screening & Diagnosis
    • 4.1.2. Tumor Identification
    • 4.1.3. Surveillance
  • 4.2. Global Artificial Intelligence in Cancer Diagnostics Market by Type
    • 4.2.1. Breast Cancer
    • 4.2.2. Prostate Cancer
    • 4.2.3. Lung Cancer
    • 4.2.4. Colorectal Cancer
    • 4.2.5. Others (Cervical Cancer, Blood Cancer, Bone Cancer, and Other)
  • 4.3. Global Artificial Intelligence in Cancer Diagnostics Market by End User
    • 4.3.1. Hospitals
    • 4.3.2. Diagnostic Centers
    • 4.3.3. Research Organization
    • 4.3.4. Medical Institute and Academics

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Therapixel
  • 6.2. Sophia Genetics SA
  • 6.3. Freenome Holdings, Inc.
  • 6.4. Tempus Labs, Inc.
  • 6.5. Janssen Pharmaceuticals
  • 6.6. Path AI Inc.
  • 6.7. DeepMind Technologies Ltd.
  • 6.8. Cerner Corp.
  • 6.9. RaySearch Laboratories
  • 6.10. Flatiron health
  • 6.11. Whiterabbit.ai
  • 6.12. Oncology Analytics Inc.
  • 6.13. Oncora Medical
  • 6.14. Ibex Medical Analytics Ltd.
  • 6.15. 4basecare Onco Solutions Pvt. Ltd .

LIST OF TABLES

  • 1. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 2. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SCREENING AND DIAGNOSIS MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER TUMOR IDENTIFICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SURVEILLANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BREAST CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PROSTATE CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LUNG CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 9. GLOBAL ARTIFICIAL INTELLIGENCE IN COLORECTAL CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 10. GLOBAL ARTIFICIAL INTELLIGENCE IN OTHER TYPES OF CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS BY HOSPITALS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 14. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 15. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER MEDICAL INSTITUTE AND ACADEMICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 16. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 21. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 22. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 23. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 24. EUROPEAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 29. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 2. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SCREENING AND DIAGNOSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER TUMOR IDENTIFICATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER SURVEILLANCE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 6. GLOBAL ARTIFICIAL INTELLIGENCE IN BREAST CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PROSTATE CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL ARTIFICIAL INTELLIGENCE IN LUNG CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL ARTIFICIAL INTELLIGENCE IN COLORECTAL CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL ARTIFICIAL INTELLIGENCE IN OTHER TYPES OF CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTICS MARKET SHARE ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 12. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER HOSPITAL MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER RESEARCH ORGANIZATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTIC BY CANCER MEDICAL INSTITUTE AND ACADEMICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. US ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. CANADA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. UK ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. FRANCE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. GERMANY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. ITALY ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. SPAIN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF EUROPE ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. INDIA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. CHINA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. JAPAN ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. SOUTH KOREA ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD ARTIFICIAL INTELLIGENCE IN CANCER DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)